ArticleEvolutionary applications2017
Cancer: A disease at the crossroads of trade-offs.
Article in Evolutionary applications, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed.
- No genome-wide correlations and little shared genetic architecture between reproductive life-history traits and estrogen receptor-positive breast cancer risk.Molecular biology and evolution · 2026Article
- Pathogenic variation in human DNA damage repair genes was originated from the evolutionary process of modern humans.Genes & diseases · 2026Review
- Symbiont Reintroduction Alters Tumor Progression and Life-History Traits in the Tumor-Bearing Freshwater CnidarianEcology and evolution · 2026Article
- When cells rebel: a comparative genomics investigation into marsupial cancer susceptibility.Molecular biology and evolution · 2026Article
- Leveraging comparative phylogenetics for evolutionary medicine: applications to comparative oncology.Evolution, medicine, and public health · 2026Article
- Towards a more robust comparative oncology: a Bayesian reanalysis of Peto's paradox and discussion of comparative cancer risk studies in vertebrates.Royal Society open science · 2025Article
- Vertical Cancer Transmission via Asexual Fragmentation and Associated Cancer Prevalence.Evolutionary applications · 2025Article
- Advances in Monoclonal Antibody Therapies for Triple-Negative Breast Cancer: Immunotherapeutic and Targeted Strategies.Current molecular medicine · 2025Review
- Normal tissue transcriptional signatures for tumor-type-agnostic phenotype prediction.Scientific reports · 2024Article
- Approaches and methods to study wildlife cancer.The Journal of animal ecology · 2024Review
- The complex effects of modern oncogenic environments on the fitness, evolution and conservation of wildlife species.Evolutionary applications · 2024Article
- Eleven inflammation-related genes risk signature model predicts prognosis of patients with breast cancer.Translational cancer research · 2024Article
- Functional transcriptional signatures for tumor-type-agnostic phenotype prediction.bioRxiv : the preprint server for biology · 2024Article
- Evolution ofGut microbes · 2023Article
- Cancer hygiene hypothesis: A test from wild captive mammals.Ecology and evolution · 2023Article
- Transmissible cancer and longitudinal telomere dynamics in Tasmanian devils (Sarcophilus harrisii).Molecular ecology · 2022Article
- Population genetics of clonally transmissible cancers.Nature ecology & evolution · 2022Review
- Multiple myeloma metabolism - a treasure trove of therapeutic targets?Frontiers in immunology · 2022Review
- The influence of evolutionary history on human health and disease.Nature reviews. Genetics · 2021Review
- Systems level profiling of chemotherapy-induced stress resolution in cancer cells reveals druggable trade-offs.Proceedings of the National Academy of Sciences of the United States of America · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Central to evolutionary theory is the idea that living organisms face phenotypic and/or genetic trade-offs when allocating resources to competing life-history demands, such as growth, survival, and reproduction. These trade-offs are increasingly considered to be crucial to further our understanding of cancer. First, evidences suggest that neoplastic cells, as any living entities subject to natural selection, are governed by trade-offs such as between survival and proliferation. Second, selection might also have shaped trade-offs at the organismal level, especially regarding protective mechanisms against cancer. Cancer can also emerge as a consequence of additional trade-offs in organisms (e.g., eco-immunological trade-offs). Here, we review the wide range of trade-offs that occur at different scales and their relevance for understanding cancer dynamics. We also discuss how acknowledging these phenomena, in light of human evolutionary history, may suggest new guidelines for preventive and therapeutic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.